Inactive Instrument

News Antares

Equities

ANT

BE0003676872

Summary

Unlock all the news: Be the first to know and act before the market!

Antares Pharma Posts Higher Q4 Adjusted Earnings, Revenue; Issues 2022 Revenue Guidance	22-03-03	MT
Earnings Flash (ATRS) ANTARES PHARMA Reports Q4 Revenue $48.7M, vs. Street Est of $47.2M	22-03-03	MT
Earnings Flash (ATRS) ANTARES PHARMA Posts Q4 EPS $0.02, vs. Street Est of $0.01	22-03-03	MT
North American Morning Briefing : Oil Prices Top -3-	22-03-03	DJ
Immo-Antares NV Reports Earnings Results for the Full Year Ended November 10, 2021	22-02-23	CI
Antares Vision Closes Acquisition Of US Software Firm ACSIS	22-02-18	MT
Antares Pharma's New Drug Application Resubmission for Testosterone Replacement Therapy Receives FDA Acceptance	22-02-03	MT
Antares Pharma Secures FDA Fast Track Designation for ATRS-1902 in Acute Adrenal Insufficiency	22-01-18	MT
Antares Gets FDA Fast-Track Designation for ATRS-1902 for Adrenal Crisis Rescue	22-01-18	DJ
Antares Pharma Says its Early-Stage Study of ATRS-1902 for Acute Adrenal Insufficiency Met its Primary Objective	22-01-11	MT
Assertio Therapeutics Acquires Otrexup from Antares Pharma for $44 Million	21-12-16	MT
Exclusive-Canada's CPP Investments seeks to sell insurance groups in strategy U-turn -sources	21-12-08	RE
Antares Pharma Q3 Earnings Steady as Revenue Rises; Narrows Full-Year Sales Guidance -- Stock Drops	21-11-04	MT
Earnings Flash (ATRS) ANTARES PHARMA Posts Q3 Revenue $48.2M, vs. Street Est of $47.9M	21-11-04	MT
Lipocine : Signs Deal with Antares Pharma for Commercialization of Tlando in the US; Shares Rise Pre-Bell	21-10-18	MT
Antares Pharma : Strikes Exclusive License Agreement For Oral Testosterone Replacement Therapy in US	21-10-18	MT
Antares Pharma : Starts Phase 1 Study of ATRS-1902 Drug for Acute Adrenal Insufficiency Treatment	21-09-30	MT
Antares Vision S p A : to Add Traceability to Russian Mineral Water Producer	21-09-28	MT
Antares Vision S p A : to Join FTSE Italia Mid Cap Index on Sept. 20	21-09-02	MT
Antares Pharma : Earnings Flash (ATRS) ANTARES PHARMA Reports Q2 Revenue $45M, vs. Street Est of $43.3M	21-08-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Antares

Equities

ANT

BE0003676872

Summary

Filters